153 related articles for article (PubMed ID: 26202819)
1. Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study.
Carbonell-Abella C; Pages-Castella A; Javaid MK; Nogues X; Farmer AJ; Cooper C; Diez-Perez A; Prieto-Alhambra D
Calcif Tissue Int; 2015 Dec; 97(6):535-41. PubMed ID: 26202819
[TBL] [Abstract][Full Text] [Related]
2. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
3. Differences in persistence among different weekly oral bisphosphonate medications.
Sheehy O; Kindundu CM; Barbeau M; LeLorier J
Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
[TBL] [Abstract][Full Text] [Related]
4. Persistence with osteoporosis medication among newly-treated osteoporotic patients.
van Boven JF; de Boer PT; Postma MJ; Vegter S
J Bone Miner Metab; 2013 Sep; 31(5):562-70. PubMed ID: 23575910
[TBL] [Abstract][Full Text] [Related]
5. Adherence to osteoporosis medications amongst Singaporean patients.
Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
[TBL] [Abstract][Full Text] [Related]
6. The association between automatic generic substitution and treatment persistence with oral bisphosphonates.
Ström O; Landfeldt E
Osteoporos Int; 2012 Aug; 23(8):2201-9. PubMed ID: 22120909
[TBL] [Abstract][Full Text] [Related]
7. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
[TBL] [Abstract][Full Text] [Related]
8. Persistence with weekly alendronate therapy among postmenopausal women.
Lo JC; Pressman AR; Omar MA; Ettinger B
Osteoporos Int; 2006; 17(6):922-8. PubMed ID: 16609824
[TBL] [Abstract][Full Text] [Related]
9. Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database.
Ziller V; Kostev K; Kyvernitakis I; Boeckhoff J; Hadji P
Int J Clin Pharmacol Ther; 2012 May; 50(5):315-22. PubMed ID: 22541835
[TBL] [Abstract][Full Text] [Related]
10. Low incidence of anti-osteoporosis treatment after hip fracture.
Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
[TBL] [Abstract][Full Text] [Related]
11. Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
Ström O; Landfeldt E; Garellick G
Osteoporos Int; 2015 Jan; 26(1):315-25. PubMed ID: 25297890
[TBL] [Abstract][Full Text] [Related]
12. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
[TBL] [Abstract][Full Text] [Related]
13. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
14. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Lang A; Robbins S; Ström O
Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
[TBL] [Abstract][Full Text] [Related]
16. Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
Tan EH; Robinson DE; Jödicke AM; Mosseveld M; Bødkergaard K; Reyes C; Moayyeri A; Voss A; Marconi E; Lapi F; Reinold J; Verhamme KMC; Pedersen L; Braitmaier M; de Wilde M; Ruiz MF; Aragón M; Bosco-Levy P; Lassalle R; Prieto-Alhambra D; Sanchez-Santos MT
Osteoporos Int; 2023 Oct; 34(10):1771-1781. PubMed ID: 37436441
[TBL] [Abstract][Full Text] [Related]
17. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.
Harris ST; Reginster JY; Harley C; Blumentals WA; Poston SA; Barr CE; Silverman SL
Bone; 2009 May; 44(5):758-65. PubMed ID: 19168160
[TBL] [Abstract][Full Text] [Related]
18. [PERSIRIS study: observational study, postmarketing, prospective, to evaluate the persistence to treatment with monthly risedronate in women with osteoporosis].
Sitjar Martínez de Sas S; Aguilera de la Fuente MT; Combalía Romera J; Menacho Pascual I; González Martínez S; Altés Boronat A
Aten Primaria; 2016 May; 48(5):316-24. PubMed ID: 26363956
[TBL] [Abstract][Full Text] [Related]
19. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Curtis JR; Westfall AO; Allison JJ; Freeman A; Saag KG
Osteoporos Int; 2006; 17(8):1268-74. PubMed ID: 16724286
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
